Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City

Simon, Matthew S.; Weiss, Don; Geevarughese, Anita; Kratz, Molly M.; Cutler, Blayne; Gulick, Roy M.; Zucker, Jane R.; Varma, Jay K.; Schackman, Bruce R.

doi:10.1097/qai.0000000000000822

Cited by 9 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 42 Among those with at-risk conditions, infection with VPDs resulted in a greater number of hospitalizations and an increased length of hospital stay compared to other at-risk patients without VPDs or healthy individuals. 42 , 43 , 46 These data indicate that VPDs cause a substantial clinical burden for both patients and HCPs and subsequently the healthcare system, which could be prevented by life-course immunization.…”

Section: Discussionmentioning

confidence: 94%

Burden of vaccine-preventable diseases among at-risk adult populations in the US

Kolobova

Nyaku

Karakusevic

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Life-course immunization holds significant benefit for population health by reducing the burden of vaccine-preventable diseases (VPD) through vaccinating individuals at different stages and circumstances in life. The study aimed to determine the epidemiologic, clinical, economic, and societal burden of VPDs among at-risk adult subpopulations in the United States. A systematic literature review was conducted for articles published between January 2010 and June 2020, which identified 72 publications. There was heterogeneity in available epidemiology data, with the prevalence of VPDs ranging from 1.1% to 68.7%. Where the disease burden was described, outcomes were typically worse among high-risk subpopulations than in the general population. Several VPDs, including herpes zoster, meningococcal, and pneumococcal infections were associated with increased costs. This review suggests that subpopulations may not frequently interact with the healthcare system, or their risk factors may not be recognized by healthcare providers, and therefore individuals may not be appropriately targeted for vaccination.

show abstract

Section: Discussionmentioning

confidence: 94%

Burden of vaccine-preventable diseases among at-risk adult populations in the US

Kolobova

Nyaku

Karakusevic

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…A cost-effectiveness analysis, which accounted for herd immunity, found that vaccination was no longer costeffective when IMD incidence was fewer than 12/100,000 persons, using a threshold of US$100,000/QALY (2012 costs). 139 This analysis assessed vaccination during an outbreak of IMD among men who have sex with men with or without human immunodeficiency virus infection. A 2018 analysis, found that universal serogroup B vaccination was not cost-effective in college-aged young adults.…”

Section: Meningococcal Vaccinementioning

confidence: 99%

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines

et al. 2021

View full text Add to dashboard Cite

“…A cost-effectiveness analysis, which accounted for herd immunity, found that vaccination was no longer cost-effective when IMD incidence was fewer than 12/100,000 persons, using a threshold of US$100,000/QALY (2012 costs) ( 139 ). This analysis assessed vaccination during an outbreak of IMD among men who have sex with men with or without human immunodeficiency virus infection.…”

Section: Inactivated Vaccines In Patients With Inflammatory Bowel Diseasementioning

confidence: 99%

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines

Jones

Tse

Carroll

et al. 2021

Journal of the Canadian Association of Gastroenterology

View full text Add to dashboard Cite

Background and Aims The effectiveness and safety of vaccinations can be altered by immunosuppressive therapies, and perhaps by inflammatory bowel disease (IBD) itself. These recommendations developed by the Canadian Association of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide guidance on immunizations in adult and pediatric patients with IBD. This publication focused on inactivated vaccines. Methods Systematic reviews evaluating the efficacy, effectiveness, and safety of vaccines in patients with IBD, other immune-mediated inflammatory diseases, and the general population were performed. Critical outcomes included mortality, vaccine-preventable diseases, and serious adverse events. Immunogenicity was considered a surrogate outcome for vaccine efficacy. Certainty of evidence and strength of recommendations were rated according to the GRADE (Grading of Recommendation Assessment, Development, and Evaluation) approach. Key questions were developed through an iterative online platform, and voted on by a multidisciplinary group. Recommendations were formulated using the Evidence-to-Decision framework. Strong recommendation means that most patients should receive the recommended course of action, whereas a conditional recommendation means that different choices will be appropriate for different patients. Results Consensus was reached on 15 of 20 questions. Recommendations address the following vaccines: Haemophilus influenzae type b, recombinant zoster, hepatitis B, influenza, pneumococcus, meningococcus, tetanus-diphtheria-pertussis, and human papillomavirus. Most of the recommendations for patients with IBD are congruent with the current Centers for Disease Control and Prevention and Canada’s National Advisory Committee on Immunization recommendations for the general population, with the following exceptions. In patients with IBD, the panel suggested Haemophilus influenzae type b vaccine for patients older than 5 years of age, recombinant zoster vaccine for adults younger than 50 year of age, and hepatitis B vaccine for adults without a risk factor. Consensus was not reached, and recommendations were not made for 5 statements, due largely to lack of evidence, including double-dose hepatitis B vaccine, timing of influenza immunization in patients on biologics, pneumococcal and meningococcal vaccines in adult patients without risk factors, and human papillomavirus vaccine in patients aged 27–45 years. Conclusions Patients with IBD may be at increased risk of some vaccine-preventable diseases. Therefore, maintaining appropriate vaccination status in these patients is critical to optimize patient outcomes. In general, IBD is not a contraindication to the use of inactivated vaccines, but immunosuppressive therapy may reduce vaccine responses.

show abstract

Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City

Abstract: Vaccination during an IMD outbreak among MSM with and without HIV infection was projected to avert IMD cases and deaths and could be cost-effective depending on IMD incidence, case fatality, and herd immunity.

Cited by 9 publications

References 28 publications

Burden of vaccine-preventable diseases among at-risk adult populations in the US

Burden of vaccine-preventable diseases among at-risk adult populations in the US

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines

Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 2: Inactivated Vaccines

Contact Info

Product

Resources

About